{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:15:18Z","timestamp":1793841318071,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pcd.2021.12.007","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T21:48:49Z","timestamp":1639777729000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Yaping","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingge","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pcd.2021.12.007_bib0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcd.2021.12.007_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pcd.2021.12.007_bib0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.pcd.2021.12.007_bib0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.pcd.2021.12.007_bib0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.pcd.2021.12.007_bib0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.pcd.2021.12.007_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1574886314666190206164647","article-title":"Safety of SGLT2 inhibitors in patients with diabetes mellitus","volume":"14","author":"Singh","year":"2019","journal-title":"Curr. Drug Saf."},{"issue":"2","key":"10.1016\/j.pcd.2021.12.007_bib0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 inhibitors: an overview","volume":"13","author":"Singh","year":"2018","journal-title":"Curr. Drug Saf."},{"issue":"1","key":"10.1016\/j.pcd.2021.12.007_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1534734619878090","article-title":"Canagliflozin and amputation risk: evidence so far","volume":"19","author":"Papadokostaki","year":"2020","journal-title":"Int. J. Low. Extrem. Wounds"},{"issue":"5","key":"10.1016\/j.pcd.2021.12.007_bib0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13647","article-title":"Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers","volume":"21","author":"Yang","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2021.12.007_bib0055","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.pcd.2021.12.007_bib0060","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/db17-0934","article-title":"DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring","volume":"67","author":"Long","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.pcd.2021.12.007_bib0065","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/892706","article-title":"Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes","volume":"2012","author":"Marfella","year":"2012","journal-title":"Exp. Diabetes Res."},{"issue":"1","key":"10.1016\/j.pcd.2021.12.007_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12967-017-1145-4","article-title":"Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing","volume":"15","author":"Seo","year":"2017","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.pcd.2021.12.007_bib0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dsx.2015.04.006","article-title":"Wound healing effects of dipeptidyl peptidase-4 inhibitors: an emerging concept in management of diabetic foot ulcer\u2014a review","volume":"10","author":"Saboo","year":"2016","journal-title":"Diabetes Metab. Syndr."},{"issue":"10","key":"10.1016\/j.pcd.2021.12.007_bib0080","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/dc20-0267","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study","volume":"43","author":"Yu","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pcd.2021.12.007_bib0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.pcd.2021.12.007_bib0090","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study","volume":"20","author":"Adimadhyam","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.pcd.2021.12.007_bib0095","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","volume":"16","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.pcd.2021.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.pcd.2021.12.007_bib0105","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.pcd.2021.12.007_bib0110","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study","volume":"20","author":"Yuan","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.pcd.2021.12.007_bib0115","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"issue":"17","key":"10.1016\/j.pcd.2021.12.007_bib0120","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pcd.2021.12.007_bib0125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991821002230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991821002230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:59:49Z","timestamp":1761695989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991821002230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1751991821002230"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2021.12.007","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2021.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}